Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the…

By J. Vermorken, J. Trigo, R. Hitt, P. Koralewski, E. Díaz-Rubio, F. Rolland, R. Knecht, N. Amellal, A. Schueler, J. Baselga. Journal of Clinical Oncology, 2007

853 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology, Otorhinolaryngology

View Paper: https://www.semanticscholar.org/paper/34f2c2b64f545265a82b975153c1615f215b2309

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. M. Dolled-Filhart
2. Timothy A. Chan

Citations in the corpus

• Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells (2018, background): “Cetuximab is used in the standard care regimen for SCCHN (Vermorken et al., 2007).”
• Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort (2016, background): “Age, median (range), years 60 (25-84) Male 110 (83) Race White 95 (72) Asian 29 (22) Other 8 (6) ECOG performance status 0 38 (29) 1 94 (71) Smoking status* Smoked 81 (61) Never smoked 51 (39) HPV status HPV associated 28 (21) Non–HPV associated 104 (79) Sum of target lesions at baseline, median (ra”
• The head and neck cancer immune landscape and its immunotherapeutic implications. (2016, background): “Cetuximab affords only modest response rates (10%–15%) as monotherapy, and there are no known biomarkers of response (10, 11).”